Released Aug 9, 2022, after the close
10-Q filed Aug 9, 2022, 40 days after period end · 0001564590-22-028763
Q2 2022 · 10-Q
Revenue—
Net Income-$24.46M-$24.46M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.51-$0.51 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$24,573,000N/M
Operating Cash Flowderived-$17,885,000N/M
Free Cash Flowderived-$17,885,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | — | — | $39.38M | $3.08M |
| Net Income | -$24.46M | -$23.60M | $7.27M | -$18.50M |
| EPS Diluted | -$0.51 | -$0.55 | $0.19 | -$0.72 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR